RAPID is the first and only FDA-approved trial to evaluate Rapamycin in Older Adults with Periodontal Disease.
Aging is the single greatest risk factor for many diseases that affect older adults, such as cardiovascular disease, Alzheimer’s Disease, and periodontal disease. Yet, we treat such diseases individually rather than targeting the underlying process of age. The inhibition of mTOR via rapamycin has been reported to extend lifespan and healthspan in laboratory animals, and studies have shown it to improve immune response in older adults.
Who may participate?
Joining a research study is an important and personal choice.
RAPID may be an option if you are:
- Over the age of 50.
- Think you have or have been diagnosed with periodontal disease.
- Have not had a cleaning in the past six (6) months.
There are other requirements for participating in the study. The study team will explain these to you.
If you are interested in enrolling, please visit https://www.rapamycintrial.com/sign-up
HALO affiliated faculty: Jonathan An
